248 related articles for article (PubMed ID: 34129318)
1. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
Lu ZD; Chen YF; Shen S; Xu CF; Wang J
ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
[TBL] [Abstract][Full Text] [Related]
2. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
[TBL] [Abstract][Full Text] [Related]
3. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
Heo MB; Cho MY; Lim YT
Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
[TBL] [Abstract][Full Text] [Related]
4. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
5. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
6. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases.
Liu Y; Crowe WN; Wang L; Lu Y; Petty WJ; Habib AA; Zhao D
Nat Commun; 2019 Nov; 10(1):5108. PubMed ID: 31704921
[TBL] [Abstract][Full Text] [Related]
7. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
[TBL] [Abstract][Full Text] [Related]
9. Activation of RIG-I/MDA5 Signaling and Inhibition of CD47-SIRPα Checkpoint with a Dual siRNA-Assembled Nanoadjuvant for Robust Cancer Immunotherapy.
Xu X; Li S; Yu W; Yao S; Fan H; Guo Z
Angew Chem Int Ed Engl; 2024 Mar; 63(10):e202318544. PubMed ID: 38194267
[TBL] [Abstract][Full Text] [Related]
10. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.
Rao L; Wu L; Liu Z; Tian R; Yu G; Zhou Z; Yang K; Xiong HG; Zhang A; Yu GT; Sun W; Xu H; Guo J; Li A; Chen H; Sun ZJ; Fu YX; Chen X
Nat Commun; 2020 Sep; 11(1):4909. PubMed ID: 32999291
[TBL] [Abstract][Full Text] [Related]
11. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of doxorubicin and STING agonist cGAMP for enhanced antitumor immunity.
Xie Y; Li K; Liang J; Wang K; Gong Z; Chen X
Int J Pharm; 2024 Apr; 654():123955. PubMed ID: 38423155
[TBL] [Abstract][Full Text] [Related]
13. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
14. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
16. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
[TBL] [Abstract][Full Text] [Related]
17. Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.
Koshy ST; Cheung AS; Gu L; Graveline AR; Mooney DJ
Adv Biosyst; 2017 Feb; 1(1-2):. PubMed ID: 30258983
[TBL] [Abstract][Full Text] [Related]
18. Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity.
Choi Y; Nam GH; Kim GB; Kim S; Kim YK; Kim SA; Kim HJ; Lee EJ; Kim IS
Cancer Gene Ther; 2021 Sep; 28(9):960-970. PubMed ID: 34349240
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
